Classical Hodgkin Lymphoma

Pembrolizumab extended PFS compared with brentuximab vedotin for patients with relapsed or refractory classic Hodgkin lymphoma, according to study results presented during the ASCO20 Virtual Scientific Program.

Pembrolizumab significantly extended PFS compared with brentuximab vedotin among patients with relapsed or refractory classical Hodgkin lymphoma, according to randomized phase 3 study results released by the agent’s manufacturer.

Healio spoke with Ash A. Alizadeh, MD, PhD, associate professor, divisions of oncology & hematology, Stanford Cancer Institute, about the potential of liquid biopsy in lymphoma.

The FDA granted regenerative medicine advanced therapy designation to Tessa Therapeutics’ CD30-directed autologous chimeric antigen receptor T-cell therapy for the treatment of patients with relapsed or refractory CD30-postive classical Hodgkin lymphoma, according to a press release issued by the manufacturer.